Boji Pharmaceuticals: signed a "Technology Transfer Agreement" to transfer a total of 14 million yuan

Boji Pharmaceutical announced that the company has signed a "Technology Transfer Agreement" with Chengdu Push Pharmaceutical Co., Ltd. The company will transfer the current technological achievements of the "Fluconazole Ear Drops" to Push Pharmaceutical, with a total transfer fee of 14 million RMB. The signing of this contract does not require approval from the company's board of directors or shareholders' meeting, and does not constitute a related party transaction or a major asset restructuring. Push Pharmaceutical is not a person subject to enforcement for dishonesty, and has no relation with the company. In the past three fiscal years, Push Pharmaceutical and the company have also signed supplementary agreements for pre-clinical research projects of "Homatropine Hydrobromide Eye Drops" and "Diclofenac Sodium Eye Drops", with a total contract amount of 2.7918 million RMB. The company recognizes revenue based on the progress of the project, and the signing of the supplementary agreements does not have a significant impact on the operating performance of the current fiscal year.